[Effect of human recombinant erythropoietin (rhuEPO) on platelet phospholipids in chronically hemodialysed].
An important role in the formation of haemostasis defects in haemodialysed patients play phospholipids. The disturbances of platelet activity play an essential part in platelet structure and function. In uraemic patients changed plasma lipid pattern is observed, as well as positive influence of human recombinant erythropoietin (rhuEPO) on some plasma lipid disorders in these patients. The aim of this study was to investigate rhuEPO influence on platelet phospholipid composition in haemodialysed patients. RhuEPO was applied subcutaneously, 2000j twice a week. Before rhuEPO treatment significant decrease of phosphatidylethanolamine (PE), phosphatidylinositol (PI) and phosphatidylcholine (PC) contents was observed, as compared with control group. After rhuEPO treatment a significant increase of PE and PC contents was noted. The obtained results suggest that rhuEPO partially normalizes changed platelet phospholipids composition, but detailed mechanism of this influence is unclear.